CYP2C19*2 and prognosis after an acute coronary syndrome: Insights from a Portuguese center

Teixeira, Rogério; Monteiro, Pedro; Marques, Gilberto; Pego, J.; Lourenço, Margarida; Tavares, Cristina; Reboredo, Alda; Monteiro, Sílvia; Gonçalves, Francisco; Ferreira, Maria João; Freitas, Mário; Ribeiro, Graça; Providência, Luí­s A.

doi:10.1016/j.repc.2012.02.001

Cited by 6 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 Almost identical results were obtained in German and Portuguese populations, and only slightly different results -in Hungarian population. [12][13][14] As far as we know, the research on the prevalence of this polymorphism in the Polish population was conducted only once in a study by Malek et al 15 The authors reported that wild-type homozygotes appear in 80% of the population, heterozygotes in 18% and mutation homozygotes in 2%. Our study has shown 73.9% of wild-type homozygotes, 24,6% of heterozygotes and 1,5% of mutation homozygotes; therefore, the data confirms the predecessors' observations.…”

Section: Discussionmentioning

confidence: 99%

Distribution of polymorphisms in the CYP2C19 and ABCB1 genes among patients with acute coronary syndrome in Lower Silesian population

et al. 2019

View full text Add to dashboard Cite

Background. Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel administered to treat patients with acute coronary syndrome (ACS) is still being used. However, despite the proven efficacy of this treatment regimen, thromboembolic complications have been observed in some individuals. The reason for this phenomenon is linked to the so-called increased responsiveness of platelets despite high platelet resistance (HPR). A significant role in HPR is attributed to genetically determined differences in the absorption and activation of clopidogrel. Objectives. The aim of the study was to assess the incidence of polymorphisms of the ABCB1 and CYPC19 genes that encode proteins involved in the absorption and metabolism of clopidogrel. Material and methods. The analysis was performed in 199 consecutive patients from Lower Silesian voivodeship (Poland) who underwent coronary angioplasty with stenting for ACS. The single nucleotide polymorphism of the CYP2C19 and ABCB1 genes was performed using a mini sequencing or restriction fragment length polymorphism method. Results. The results of this study revealed the high incidence of patients who may be unresponsive to antiplatelet treatment due to genetic causes. The CYPC19*2 allele in the form of homozygote or mutation heterozygote appeared in 26. 1% of the study population. ABCB1 (C3435C> T) polymorphism was associated with 84% of patients. The total incidence of allelic disorders of low drug absorption and metabolism reached 14.6%. Conclusions. The data obtained should prompt clinicians to use more recent antiplatelet agents (ticagrelor or prasugrel) first, instead of clopidogrel.

show abstract